Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies
CL Grandjean, F Montalvao, S Celli, D Michonneau… - Scientific Reports, 2016 - nature.com
Anti-CD20 monoclonal antibodies (mAbs) represent an effective treatment for a number of B
cell malignancies and autoimmune disorders. Glycoengineering of anti-CD20mAb may …
cell malignancies and autoimmune disorders. Glycoengineering of anti-CD20mAb may …
Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis
Anti-CD20 antibody (mAb) represents an effective strategy for the treatment of B cell
malignancies, possibly involving complement activity, antibody-dependent cellular …
malignancies, possibly involving complement activity, antibody-dependent cellular …
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated …
E Mössner, P Brünker, S Moser… - Blood, The Journal …, 2010 - ashpublications.org
CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor–dependent mechanisms during anti-CD20 antibody immunotherapy
J Uchida, Y Hamaguchi, JA Oliver, JV Ravetch… - The Journal of …, 2004 - rupress.org
Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
J Zalevsky, IWL Leung, S Karki, SY Chu… - Blood, The Journal …, 2009 - ashpublications.org
CD19, a B cell–restricted receptor critical for B-cell development, is expressed in most B-cell
malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574, has enhanced Fcγ …
malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574, has enhanced Fcγ …
[HTML][HTML] Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment
AH Turaj, K Hussain, KL Cox, MJJ Rose-Zerilli, J Testa… - Cancer cell, 2017 - cell.com
Monoclonal antibodies (mAbs) can destroy tumors by recruiting effectors such as myeloid
cells, or targeting immunomodulatory receptors to promote cytotoxic T cell responses. Here …
cells, or targeting immunomodulatory receptors to promote cytotoxic T cell responses. Here …
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
S Gallagher, S Turman, I Yusuf, A Akhgar, Y Wu… - International …, 2016 - Elsevier
B cell depletion therapy is beneficial for patients with B cell malignancies and autoimmune
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
F Montalvao, Z Garcia, S Celli, B Breart… - The Journal of …, 2013 - Am Soc Clin Investig
Anti-CD20 Ab therapy has proven successful for treating B cell malignancies and a number
of autoimmune diseases. However, how anti-CD20 Abs operate in vivo to mediate B cell …
of autoimmune diseases. However, how anti-CD20 Abs operate in vivo to mediate B cell …
A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC
K Du, Y Li, J Liu, W Chen, Z Wei, Y Luo, H Liu, Y Qi… - Molecular Therapy, 2021 - cell.com
Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody
R Herbst, Y Wang, S Gallagher, N Mittereder… - The Journal of …, 2010 - Elsevier
The pan B-cell surface antigen CD19 is an attractive target for therapeutic monoclonal
antibody (mAb) approaches. We have generated a new afucosylated anti-human (hu) CD19 …
antibody (mAb) approaches. We have generated a new afucosylated anti-human (hu) CD19 …